Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations
Open accessAbstract
Background Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide.Aims In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials.Methods A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials.Conclusions This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Guidance from the FDA also addressed statistical methodology as it relates to meeting trial objectives during the pandemic.
“Guidance from the FDA also addressed statistical methodology as it relates to meeting trial objectives during the pandemic.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 69 · Cited by 88
Research works printed but not linked: 3
- [23]Xu Z Shi L Wang Y Zhang J Huang L Zhang C Liu S Zhao P Liu H Zhu L Tai Y Bai C Gao T Song J Xia P Dong J Zhao J Wang FS Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir Med 2020 8 4 420 422 10.1016/S2213-2600(20)30076-X 32085846 PMC7164771 · DOI · Paper page
- [72]Guan WJ Ni ZY Hu Y Liang WH Ou CQ He JX Clinical characteristics of coronavirus disease 2019 in China N Engl J Med 2020 10.1056/NEJMoa2002032 32109013 PMC7092819 · DOI · Paper page
- [74]Boettler T Newsome PN Mondelli MU Maticic M Cordero E Cornberg M Berg T Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper JHEP Rep. 2020 2 3 100113 10.1016/j.jhepr.2020.100113 32289115 PMC7128473 · DOI · Paper page
- Authors
- APASL Covid-19 Task Force, Lau, G., & Sharma, M.
- Affiliations
- Chinese PLA General Hospital (CN)
- Institute of Liver and Biliary Sciences (IN)
- Corresponding author
- Lau, George
- Sharma, Manoj
- ORCID
- Lau, George
- Venue
- Hepatology International
- Published
- 2020-05-23
- Volume
- 14
- Issue
- 4
- Pages
- 415-428
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- PMC
- PMC7245190
- OpenAlex
- W3027222578
- Cited by
- 88
- References
- 69
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 9 · 2022: 17 · 2021: 28 · 2020: 23
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology International (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- COVID-19 pandemic, liver transplantation, liver disease management, liver injury, autoimmune liver disease, chronic liver disease, clinical trial conduct, consensus recommendations
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Humans, Liver Diseases, Practice Patterns, Physicians', Pneumonia, Viral, Liver Transplantation, Practice Guidelines as Topic, Coronavirus Infections, Patient Selection, Consensus, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
